Wedbush Initiates Coverage On Artiva Biotherapeutics with Outperform Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with an Outperform rating and a price target of $18.
August 13, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has initiated coverage on Artiva Biotherapeutics with an Outperform rating and a price target of $18.
The initiation of coverage with an Outperform rating and a price target of $18 by a reputable analyst is likely to positively impact the stock price of Artiva Biotherapeutics in the short term. This rating suggests strong potential for growth and can attract investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100